Goldman Sachs Upgrades Vir Biotechnology (VIR) to Buy; Differentiated Approach to COVID Antibody
Tweet Send to a Friend
(Updated - September 14, 2020 5:00 AM EDT)(updating comment)Goldman Sachs analyst Paul Choi upgraded Vir Biotechnology (NASDAQ: VIR) from Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
